Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Ituxredi (rituximab biosimilar)
i
Other names:
DRL_RI
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Abbott, CinnaGen, Dr. Reddy’s, EMD Serono, Fresenius Kabi, R-Pharm
Drug class:
CD20 inhibitor
Related drugs:
‹
rituximab (174)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
mosunetuzumab-axgb (2)
rituximab-arrx (2)
IMM0306 (2)
IGM-2323 (2)
AR160 (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
ACTR087 (0)
ALETA-001 (0)
AcellBia (rituximab biosimilar) (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CM355 (0)
CMG1A46 (0)
DI Leu16 IL-2 (0)
(0)
GB241 (rituximab biosimilar) (0)
GB261 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MIL62 (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
ocrelizumab (0)
PRO131921 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
IGN002 (0)
AME-133v (0)
XmAb13676 (0)
TG20 (rituximab biosimilar) (0)
rituximab (174)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
mosunetuzumab-axgb (2)
rituximab-arrx (2)
IMM0306 (2)
IGM-2323 (2)
AR160 (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
ACTR087 (0)
ALETA-001 (0)
AcellBia (rituximab biosimilar) (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CM355 (0)
CMG1A46 (0)
DI Leu16 IL-2 (0)
(0)
GB241 (rituximab biosimilar) (0)
GB261 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MIL62 (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
ocrelizumab (0)
PRO131921 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
IGN002 (0)
AME-133v (0)
XmAb13676 (0)
TG20 (rituximab biosimilar) (0)
›
Associations
News
Trials
Filter by
Latest
10ms
FLINTER: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (clinicaltrials.gov)
P3, N=317, Completed, Dr. Reddy's Laboratories Limited | Active, not recruiting --> Completed
10 months ago
Trial completion
|
CD20 (Membrane Spanning 4-Domains A1)
|
Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
12ms
RI-01-007: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (clinicaltrials.gov)
P3, N=140, Completed, Dr. Reddy's Laboratories Limited | Active, not recruiting --> Completed
12 months ago
Trial completion
|
Ituxredi (rituximab biosimilar)
1year
Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era. (PubMed, Front Oncol)
Reditux™ and Ristova were comparable in real-world setting. ISRCTN registry, identifier (ISRCTN13301166).
1 year ago
Journal • Real-world evidence • Real-world
|
BCL2 (B-cell CLL/lymphoma 2)
|
Ituxredi (rituximab biosimilar)
2years
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=39, Completed, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jul 2022
2 years ago
Trial completion • Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Ituxredi (rituximab biosimilar)
over2years
FLINTER: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (clinicaltrials.gov)
P3, N=317, Active, not recruiting, Dr. Reddy's Laboratories Limited | Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Mar 2023 | Trial primary completion date: Sep 2020 --> Sep 2022
over 2 years ago
Enrollment closed • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
3years
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=39, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Dec 2022 --> Jul 2024 | Trial primary completion date: Mar 2021 --> Jul 2021
3 years ago
Clinical • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
almost4years
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=39, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting
almost 4 years ago
Clinical • Enrollment closed
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login